Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

Haematologica. 2020 Mar;105(3):e116-e120. doi: 10.3324/haematol.2018.212308. Epub 2019 Jul 18.

Authors

Esperanza M Algarín¹, Andrea Díaz-Tejedor¹, Pedro Mogollón¹, Susana Hernández-García¹, Luis A Corchete¹, Laura San-Segundo¹, Montserrat Martín-Sánchez¹, Lorena González-Méndez¹, Marie Schoumacher², Sebastien Banquet², Laurence Kraus-Berthier², Ioana Kloos², Alix Derreal², Ensar Halilovic³, Heiko Maacke⁴, Norma C Gutiérrez¹, María-Victoria Mateos¹, Teresa Paíno¹, Mercedes Garayoa¹, Enrique M Ocio^{5

6}

Affiliations

¹ University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
² Institut de Recherches Servier, Suresnes, France.
³ Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
⁴ Novartis Institutes for Biomedical Research, Basel, Switzerland.
⁵ University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain ocioem@unican.es.
⁶ University Hospital Marqués de Valdecilla (IDIVAL); University of Cantabria, Santander, Spain.

No abstract available

Publication types

Letter

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Cell Line, Tumor
Humans
Multiple Myeloma* / drug therapy
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins c-bcl-2 / genetics
Pyrimidines
Sulfonamides
Thiophenes

Substances

Bridged Bicyclo Compounds, Heterocyclic
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins c-bcl-2
Pyrimidines
S63845
Sulfonamides
Thiophenes
venetoclax